Menstrual Migraine (Hormone Headache): A Detailed Guide

Last Updated on April 9, 2026 by Nurseslab.in Editorial Team

Overview

Menstrual migraine is migraine whose attacks show a consistent relationship to menstruation. It is sometimes called a hormone headache, but that informal term can be misleading: the disorder is migraine, a neurological disease involving sensory processing and the trigeminovascular system, rather than an ordinary headache caused simply by “having hormones.” The usual trigger is the rapid fall in oestrogen shortly before bleeding begins, with prostaglandin release during menstruation also contributing in some people.

Attacks around menstruation are often longer, more severe, more nauseating, and more likely to recur than attacks at other times. They usually occur without aura, even in a person who occasionally has aura with non-menstrual attacks. Menstrual migraine can begin after menarche, change with contraception or pregnancy, become less predictable during perimenopause, and often improves after natural menopause when hormone fluctuations settle.

How the Menstrual Cycle Influences Migraine

During a typical ovulatory cycle, oestrogen rises during the follicular phase, peaks before ovulation, falls briefly, rises again with progesterone during the luteal phase, and then drops sharply if pregnancy does not occur. This late-luteal oestrogen withdrawal can lower the threshold for a migraine attack. The effect appears to involve serotonin signalling, calcitonin gene-related peptide, cortical excitability, pain modulation, blood vessels, and sensitisation of trigeminal pathways.

Prostaglandins released from the uterine lining at the start of menstruation can contribute to inflammation, cramps, nausea, diarrhoea, and headache. Blood loss, sleep disruption, missed meals, dehydration, stress, and iron deficiency may further reduce migraine threshold. The relationship is therefore biological but multifactorial. A single hormone level is rarely useful because timing and rate of change matter more than an isolated measurement.

Diagnostic Subtypes

• Pure menstrual migraine: Migraine attacks occur only in the menstrual window—day 1 plus or minus 2, meaning from two days before bleeding begins through the third day of bleeding—in at least two of three cycles, with no attacks at other times.
• Menstrually related migraine: Attacks occur in the same menstrual window in at least two of three cycles but also occur at other times.
• Non-menstrual migraine: Attacks do not show the required repeated relationship to the menstrual window.
• Menstrual migraine with aura: Recognised in the diagnostic appendix but less common; most menstrual attacks are without aura.

A prospective diary for at least three cycles is the most reliable practical way to identify the pattern. Recalling that headaches “often happen with periods” is less accurate because frequent migraine will sometimes overlap menstruation by chance.

Symptoms and Phases of an Attack

• Prodrome: Fatigue, yawning, food craving, thirst, mood change, neck stiffness, poor concentration, or increased urination may begin hours or a day before pain.
• Aura: Reversible visual, sensory, or speech symptoms usually develop gradually and last 5 to 60 minutes. Aura is not required and is relatively uncommon in menstrual attacks.
• Headache: Moderate or severe throbbing or pulsating pain, often one-sided but sometimes bilateral, worsened by routine activity.
• Associated symptoms: Nausea, vomiting, light sensitivity, sound sensitivity, smell sensitivity, dizziness, scalp tenderness, and difficulty thinking.
• Postdrome: Fatigue, cognitive slowing, mood change, weakness, or residual head discomfort may continue after pain resolves.

Untreated migraine attacks commonly last 4 to 72 hours. Menstrual attacks may persist longer within that range, recur the next day, or respond less completely to a treatment that works well at other times. Severe vomiting can make tablets unreliable, so route of administration matters.

Common Triggers and Aggravating Factors

• Rapid oestrogen withdrawal before spontaneous bleeding or during a hormone-free contraceptive interval.
• Prostaglandin release, painful periods, or heavy bleeding.
• Missed meals, fasting, dehydration, alcohol, or abrupt caffeine change.
• Too little, too much, or irregular sleep.
• Stress, recovery after stress, travel, or shift work.
• Bright light, strong odours, noise, heat, or motion sensitivity.
• Iron deficiency or anaemia from heavy menstrual bleeding.
• Medication overuse, especially frequent acute pain medicines.
• Perimenopausal hormone fluctuation, postpartum oestrogen withdrawal, or changes in hormonal therapy.

Diagnostic Evaluation

1. Headache and cycle diary: Record headache days, start and stop times, menstrual bleeding, pain severity, disability, aura, nausea, medicines, response, and possible triggers for at least three cycles.
2. Migraine history: Clarify pain quality, location, duration, activity sensitivity, associated symptoms, age at onset, frequency, family history, and change over time.
3. Aura assessment: Determine whether symptoms spread gradually, are fully reversible, and last within the usual time range. Sudden negative symptoms require urgent exclusion of stroke.
4. Menstrual and reproductive history: Review cycle regularity, heavy bleeding, pain, contraception, fertility treatment, pregnancy possibility, postpartum status, perimenopause, and hormone replacement therapy.
5. Medication review: Document acute-medicine days, preventive therapy, contraceptives, oestrogen exposure, anticoagulants, blood-pressure medicines, and interacting drugs.
6. Vascular risk assessment: Check smoking, hypertension, diabetes, high cholesterol, obesity, clotting history, cardiovascular disease, and family history—especially when aura or oestrogen therapy is present.
7. Physical and neurological examination: Measure blood pressure and assess vision, eye movements, cranial nerves, strength, sensation, reflexes, coordination, gait, and signs of another disorder.
8. Pregnancy testing: Consider when biologically possible before medicines or investigations that may affect pregnancy.
9. Blood tests: Not required to diagnose menstrual migraine, but full blood count, ferritin, thyroid testing, or metabolic studies may be used when heavy bleeding, anaemia, thyroid disease, or another condition is suspected.
10. Brain imaging: MRI or CT is unnecessary for a stable typical pattern with a normal examination. Imaging is used for red flags, a major change, abnormal neurological findings, or concern for secondary headache.

Differential Diagnosis

• Tension-type headache, which is usually pressing rather than pulsating and less aggravated by activity.
• Medication-overuse headache caused by frequent acute-treatment use.
• Headache from iron-deficiency anaemia, dehydration, sleep disorder, or thyroid disease.
• Premenstrual syndrome or premenstrual dysphoric disorder with headache among broader cyclical symptoms.
• Endometriosis or severe dysmenorrhoea with secondary headache from pain and prostaglandins.
• Vestibular migraine when dizziness or vertigo dominates.
• Cluster headache or another trigeminal autonomic cephalalgia.
• Idiopathic intracranial hypertension, cerebral venous sinus thrombosis, stroke, subarachnoid haemorrhage, meningitis, brain tumour, or another secondary cause when red flags are present.

Treatment Goals and Strategy

• Stop individual attacks quickly and restore function.
• Prevent recurrence later in the same menstrual window.
• Reduce nausea and vomiting so treatment can be absorbed.
• Use short-term prevention when cycles and attacks are predictable.
• Use continuous prevention when attacks also occur frequently outside menstruation or cycles are irregular.
• Avoid medication overuse, vascular harm, and unsafe hormone exposure.
• Coordinate headache control with contraception, heavy bleeding, pregnancy goals, and menopausal care.

Acute Treatment

• Treat early: Take the prescribed acute medicine when migraine pain starts; some people are instructed to treat during aura, but timing depends on the medicine.
• Triptans: Sumatriptan, rizatriptan, zolmitriptan, eletriptan, almotriptan, or another triptan may be selected. Cardiovascular contraindications and drug interactions must be reviewed.
• Anti-inflammatory medicines: Ibuprofen, naproxen, diclofenac, or another NSAID may be used when medically suitable. Avoid or modify use with ulcer disease, kidney disease, anticoagulation, pregnancy, or NSAID-sensitive asthma.
• Combination therapy: A triptan plus an NSAID may work better and reduce recurrence when either alone is insufficient.
• Gepants: A CGRP-receptor antagonist may be an option when triptans are ineffective, poorly tolerated, or unsuitable; access varies by country.
• Antiemetics: Metoclopramide, prochlorperazine, or another prescribed medicine can treat nausea and improve oral drug absorption.
• Non-oral routes: Nasal spray, injection, orally dissolving formulation, or another non-oral option may be preferable with rapid onset or vomiting.
• Avoid routine opioids or butalbital: They can worsen disability, recurrence, dependence, and medication-overuse headache.

Short-Term Perimenstrual Prevention

Mini-prevention is considered when attacks are disabling, occur predictably around menstruation, and are not adequately controlled by acute treatment. Therapy commonly begins one or two days before the expected migraine window and continues for approximately five to seven days. Exact timing and dose require clinician guidance.

• Long-acting triptan: Frovatriptan or naratriptan is commonly used; zolmitriptan is another studied option. Avoid combining different triptans or ergot drugs without explicit instruction.
• NSAID: Scheduled naproxen or another anti-inflammatory medicine may help both migraine and menstrual cramps when safe.
• Magnesium: Some clinicians recommend magnesium beginning in the latter part of the cycle or during the menstrual window. Product, dose, kidney function, and gastrointestinal effects should be reviewed.
• Oestrogen supplementation: Transdermal oestrogen during the expected withdrawal window may help selected patients with predictable natural cycles. Incorrect timing can postpone rather than prevent an attack.
• Limitations: Irregular cycles make scheduling unreliable, and repeated triptan or NSAID exposure can contribute to medication overuse or adverse effects.

Continuous Preventive Treatment

Daily or regularly scheduled prevention is considered when migraine is frequent throughout the month, cycles are unpredictable, mini-prevention fails, acute medicines are overused, or disability remains high.

• CGRP-targeted treatment: Monoclonal antibodies or preventive gepants can reduce migraine frequency; pregnancy planning, constipation, blood pressure, and local access may influence selection.
• Beta blockers: Propranolol or another agent may suit people without asthma, marked bradycardia, or low blood pressure.
• Topiramate: Effective for many patients but can cause cognitive effects, tingling, weight loss, kidney stones, and serious fetal risk. Reliable pregnancy prevention and preconception review are essential.
• Tricyclic or serotonin–noradrenaline medicines: Amitriptyline or venlafaxine may help selected patients, especially with sleep or mood comorbidity.
• Candesartan: An option for some adults but unsuitable in pregnancy.
• OnabotulinumtoxinA: Used for chronic migraine meeting frequency criteria, not solely for a few menstrual attacks.
• Neuromodulation: Non-invasive devices may be considered when medicines are unsuitable or as adjuncts.

Hormonal Contraception and Hormone Stabilisation

Hormonal treatment can improve, worsen, or leave migraine unchanged. The aim is often to reduce oestrogen withdrawal by shortening or eliminating the hormone-free interval. Contraceptive effectiveness, bleeding control, aura status, smoking, blood pressure, age, thrombosis history, and other vascular risks must be assessed together.

• Combined hormonal contraception: Continuous or extended-cycle regimens can reduce withdrawal attacks in appropriately selected people with migraine without aura.
• Migraine with aura: Oestrogen-containing combined hormonal contraception is generally contraindicated under major contraceptive safety guidelines because aura and oestrogen both increase ischaemic stroke risk.
• Progestogen-only contraception: Pills, implants, injections, or intrauterine systems may be suitable when oestrogen is unsafe. Migraine response varies.
• New aura after starting hormones: Stop self-management changes and obtain prompt medical review; sudden neurological symptoms require urgent assessment.
• Oestrogen bridge: Patch or gel around the hormone-free interval is specialist-directed and not appropriate for every patient.

Pregnancy, Postpartum, and Breastfeeding

Migraine without aura often improves during pregnancy as oestrogen becomes more stable, although this is not universal. A new severe headache in pregnancy or after birth must not be assumed to be migraine because pre-eclampsia, cerebral venous thrombosis, stroke, pituitary disease, and other secondary causes are more likely during this period.

• Review preventive and acute medicines before conception whenever possible.
• Avoid topiramate, valproate, angiotensin-receptor blockers, ergot derivatives, and other contraindicated drugs according to specialist advice.
• Use the lowest-risk effective acute plan agreed with obstetric and headache clinicians.
• After delivery, abrupt oestrogen withdrawal, sleep loss, dehydration, and irregular meals can trigger recurrence.
• Check medicine compatibility with breastfeeding rather than stopping needed treatment automatically.

Perimenopause and Menopause

Perimenopause can worsen migraine because ovarian hormone levels become erratic and cycles less predictable. Mini-prevention may therefore become difficult to time. After natural menopause, attacks often improve as oestrogen stabilises, although some people continue to have migraine. Hormone replacement therapy may improve menopausal symptoms but can either improve or worsen migraine.

• Use the lowest effective hormone dose for the shortest appropriate duration based on menopausal indication, not migraine alone.
• Transdermal oestrogen often produces steadier levels than oral therapy and may be preferred when clinically suitable.
• Continuous regimens may reduce hormone-withdrawal fluctuation.
• Migraine aura and cardiovascular risks require individual review before systemic oestrogen.
• New or changing headache after age 50 warrants assessment rather than automatic attribution to hormones.

Self-Management and Lifestyle

• Keep sleep and wake times as regular as practical.
• Eat regular meals, especially breakfast, and plan snacks during the menstrual window.
• Maintain hydration and avoid abrupt caffeine withdrawal.
• Use regular aerobic activity and gentle movement between attacks.
• Prepare a menstrual-window treatment kit with prescribed medicines, water, food, and an antiemetic.
• Use a quiet, dark environment, cooling, relaxation, or paced breathing during an attack.
• Track function, not only pain: missed work, school, caregiving, exercise, and sleep show treatment impact.
• Address heavy bleeding and iron deficiency rather than treating headache alone.

Medication-Overuse Headache

Frequent acute treatment can transform episodic migraine into more persistent headache. Risk depends on the medicine and number of treatment days, not merely the number of tablets. Triptans, opioids, ergot derivatives, and combination analgesics can cause overuse at lower monthly frequencies than simple analgesics or NSAIDs. A diary should count acute-treatment days. Increasing need for rescue medicine is a reason to improve prevention, not simply repeat doses.

Complications and Impact

• Prolonged attacks or status migrainosus lasting more than 72 hours.
• Medication-overuse headache and progression to chronic migraine.
• Dehydration, missed nutrition, sleep loss, and reduced physical activity.
• Work or school absence, reduced productivity, impaired caregiving, and social withdrawal.
• Anxiety about predictable monthly disability and depression related to chronic pain.
• Unsafe exposure to oestrogen when aura or major vascular risks are not recognised.
• Delayed diagnosis of heavy menstrual bleeding, anaemia, endometriosis, or another associated condition.

Key Points

Menstrual migraine is migraine linked repeatedly to the window from two days before menstruation through the third day of bleeding. Rapid oestrogen withdrawal is the principal hormonal trigger, while prostaglandins and general migraine triggers can add to the burden. Diagnosis is clinical and is best confirmed with a prospective headache and menstrual diary for at least three cycles. Treatment may combine early acute therapy, short-term perimenstrual prevention, continuous migraine prevention, and carefully selected hormonal strategies. Aura status and vascular risk are crucial because oestrogen-containing contraception is generally unsafe in migraine with aura. New neurological symptoms or a sudden severe headache require urgent assessment rather than assumption that hormones are responsible.

Nursing Care of a Patient with Menstrual Migraines (Hormone Headaches)

Nursing care focuses on headache assessment, trigger identification, acute symptom relief, menstrual-cycle tracking, medication safety, prevention strategies, and patient education.

Nursing Assessment

• Assess headache timing in relation to the menstrual cycle, including onset, duration, frequency, severity, and whether attacks occur only with menses or also at other times.
• Assess pain characteristics such as location, throbbing or pulsing quality, intensity, aggravation by movement, and effect on work, school, sleep, family responsibilities, and daily activities.
• Assess associated symptoms including nausea, vomiting, photophobia, phonophobia, dizziness, fatigue, blurred vision, aura symptoms, neck discomfort, appetite changes, and mood changes.
• Ask the patient to keep a headache and menstrual-cycle diary for at least three cycles to identify patterns, triggers, treatment response, and possible medication overuse.
• Review triggers such as missed meals, dehydration, sleep changes, stress, caffeine changes, alcohol, certain foods, bright light, strong smells, weather changes, and hormonal contraception or hormone therapy changes.
• Screen for red flags requiring urgent medical assessment, including sudden worst headache, new neurological deficit, fever, stiff neck, confusion, seizure, head injury, pregnancy-related severe headache, new headache after age 50, or rapidly worsening pattern.
• Review medications, contraception, pregnancy plans, breastfeeding status, cardiovascular risk factors, hypertension, smoking, migraine with aura, clotting history, and contraindications to triptans, NSAIDs, estrogen, or other therapies.

Priority Nursing Diagnoses

• Acute pain related to neurovascular migraine mechanisms and hormonal fluctuation.
• Nausea related to migraine attack, pain intensity, medication effects, or delayed gastric emptying.
• Disturbed sensory perception related to photophobia, phonophobia, aura, dizziness, or visual disturbance.
• Ineffective coping related to recurrent disabling headaches, work or school disruption, sleep disturbance, or anxiety about future attacks.
• Deficient knowledge related to menstrual migraine pattern, trigger control, medication use, prevention options, and warning signs.
• Risk for medication overuse headache related to frequent use of acute pain medicines, triptans, combination analgesics, or caffeine-containing products.

REFERENCES

1. Cupini, L.M., Corbelli, I. & Sarchelli, P. Menstrual migraine: what it is and does it matter?. J Neurol 268, 2355–2363 (2021). https://doi.org/10.1007/s00415-020-09726-2
2. American Migraine Foundation. Menstrual Migraine Treatment and Prevention https://americanmigrainefoundation.org/resource-library/menstrual-migraine-treatment-and-prevention/. Last updated 11/5/2021.
3. Endocrine Society. Estrogen Hormones (https://www.endocrine.org/patient-engagement/endocrine-library/hormones-and-endocrine-function/reproductive-hormones). Last updated 1/24/2022.
4. National Headache Foundation (U.S.). Menstrual Migraine (https://headaches.org/menstrual-migraine/). Last reviewed 5/4/2022.
5. National Library of Medicine (U.S.). Hormones (https://medlineplus.gov/hormones.html). Last updated 10/7/2016.
6. Moy G, Gupta V. Menstrual-Related Headache (https://www.ncbi.nlm.nih.gov/books/NBK557451/). Updated 2022 Oct 4. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-.
7. Ropper AH, Samuels MA, Klein JP, Prasad S. Adams and Victor’s Principles of Neurology. 11th ed. New York: McGraw Hill; 2019.

Stories are the threads that bind us; through them, we understand each other, grow, and heal.

JOHN NOORD

Connect with “Nurses Lab Editorial Team”

I hope you found this information helpful. Do you have any questions or comments? Kindly write in comments section. Subscribe the Blog with your email so you can stay updated on upcoming events and the latest articles.